Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements

Of the seven health tech companies that met with the government's most powerful health official this week, all but one had something in common

May 28, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Good evening. This week only, get 50% off your first year of STAT+ and enjoy unlimited access to award-winning journalism, premium data tools, discounted event tickets, and much more. Thanks for reading.

Adobe Opinion: Former FDA commissioner: 'Cost-cutting' may undo one of Trump's best drug pricing achievements Former FDA commissioner on the Trump administration's troubled decision to cut staff who were going to help create generic GLP-1s. By Scott Gottlieb Lilly to acquire biotech developing pain drugs Today's biotech news includes RFK Jr. rolling back Covid booster recommendations, a patient death in Rocket's rare disease trial, etc. By Elaine Chen Opinion: Women in medicine are held back by gendered ageism Ageism holds women physicians back from leadership roles — and even forces some out of medicine altogether. By Adaira I. Landry and Resa E. Lewiss

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser